Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Journal article
Datoo MS. et al, (2022), The Lancet. Infectious diseases
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial.
Journal article
Jenkin D. et al, (2022), The Lancet. Microbe, 3, e663 - e671
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.
Journal article
Waerlop G. et al, (2022), Frontiers in immunology, 13
A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
Journal article
Sklar MJ. et al, (2021), PLOS ONE, 16, e0256980 - e0256980
Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)
Journal article
Butler C. et al, (2021), Vaccines, 9, 851 - 851
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
Journal article
Datoo MS. et al, (2021), The Lancet, 397, 1809 - 1818
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
Journal article
Folegatti PM. et al, (2021), Vaccines, 9, 262 - 262
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 279 - 288
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 270 - 278
Factors influencing the re-emergence of plague in Madagascar.
Journal article
Alderson J. et al, (2020), Emerging topics in life sciences, 4, 411 - 421
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
Journal article
Folegatti PM. et al, (2020), The Lancet Infectious Diseases, 20, 816 - 826
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Journal article
Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826
Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers
Journal article
Venkatraman N. et al, (2019)
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Journal article
Folegatti PM. et al, (2019), Vaccines, 7, 40 - 40
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
Journal article
Folegatti PM. et al, (2019), Vaccines, 7, 33 - 33
Prime and target immunization protects against liver-stage malaria in mice
Journal article
Gola A. et al, (2018), Science Translational Medicine, 10, eaap9128 - eaap9128